Clinical Trials
93 trialsNeoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Blokhin's Russian Cancer Research Center
Wide Excision of Soft Tissue Sarcomas in Combination With Interstitial Radiation Therapy
Blokhin's Russian Cancer Research Center
Circulating Tumor DNA in Soft Tissue Sarcoma
University Health Network, Toronto
Evaluation of Performance Characteristics and Applicability in Oncology of Devices Customized Medical Devices Made by 3D Printing
Meyer Children's Hospital IRCCS
PalboSarc
Grupo Espanol de Investigacion en Sarcomas
Chidamide Combined With Toripalimab in Sarcoma
Sun Yat-sen University
Phase II Study of TAEST16001 in Soft Tissue Sarcoma
Sun Yat-sen University
Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
Xiangya Hospital of Central South University
MGMT
National Cancer Institute, Naples
SarQuantIRM
Centre Leon Berard
PROGEN_SARC
Regina Elena Cancer Institute
RAR-Immune
Centre Leon Berard
BORIS
Instituto do Cancer do Estado de São Paulo
Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma
Sun Yat-sen University
Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma
Sun Yat-sen University
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
Sun Yat-sen University
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Sun Yat-sen University
TAEST16001 in the Treatment of Soft Tissue Sarcoma
Sun Yat-sen University
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Sun Yat-sen University
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
REGOMUNE
Institut Bergonié
HyperTET
Ludwig-Maximilians - University of Munich
RADIOSARC
Centre Leon Berard
Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma
Peking University Cancer Hospital & Institute
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
Ruijin Hospital
The Effects of Observer Presence and Type on Patients' Perception of Exercise in Patients With Soft Tissue Sarcoma
Istanbul Medeniyet University
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Sun Yat-sen University
ANNA-SARC
Maria Sklodowska-Curie National Research Institute of Oncology
Effect of Negative Pressure Wound Therapy After Surgical Removal of Deep-Seated High-Malignant Soft Tissue Sarcomas of the Extremities and Trunk Wall.
Rigshospitalet, Denmark
Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer
Samsung Medical Center
OPTISARC
Centre Leon Berard
Fruquintinib in the Treatment of Soft Tissue Sarcoma
Fudan University
METROmaJX
Institut Bergonié
Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
West China Hospital
Predictive Models of Treatment Responses and Survival Outcomes in Patients With Soft Tissue Sarcoma
West China Hospital
DOREMY
The Netherlands Cancer Institute
Augmented Reality (AR): The Future of "Patient Information Leaflets
NHS Greater Glasgow and Clyde
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HSP70CTC
Charite University, Berlin, Germany
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
Fudan University
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children
Sun Yat-sen University
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
Sun Yat-sen University
Prehabilitation Soft-Tissue Sarcoma of Lower Limb
McGill University
OnkoFit II
University Hospital Tuebingen
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Fudan University
Combination Immunotherapy Targeting Sarcomas
Shenzhen Geno-Immune Medical Institute